肝细胞癌的分子靶向治疗  

Recent advances in molecular targeted therapy of hepatocellular carcinoma

作　　者：石娟娟[1] 党双锁[1] Juan-Juan Shi;Shuang-Suo Dang(Department of Infectious Diseases,the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,Shaanxi Province,China)

机构地区：[1]西安交通大学第二附属医院感染科,陕西省西安市710004

出　　处：《世界华人消化杂志》2018年第34期2008-2017,共10页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.31500650~~

摘　　要：肝细胞癌(hepatocellular carcinoma, HCC)死亡率居所有肿瘤的第二位,且近年在我国有上升趋势.因其发病隐匿、进展快、预后差,一直是研究的热点和难点.近10年来, HCC的治疗方法有了显著性进展,尤其是分子靶向药物的使用和研究,开启了HCC治疗方法的新阶段.本文就目前HCC发生发展相关信号通路及潜在分子靶点的研究现状、分子靶向治疗药物临床使用状况以及新药研发进展做了比较详细地叙述.Hepatocellular carcinoma(HCC) is the second most common cause of mortality from any type of cancer, and its mortality has risen in recent years in China. Because of its insidious onset, rapid progression, and poor prognosis, HCC has become a hot and difficult research topic. HCC therapy, especially the use and research of molecular targeted drugs, has achived significant advances and opened up a new avenue for the treatment of HCC. In this paper, we will describe the recent advances in the research of of signaling pathways and potential molecular targets, the clinical use of molecular targeted drugs, and new molecular targeted drugs for HCC.

关 键 词：肝细胞癌 分子机制 靶向治疗 靶向药物 

分 类 号：R735.7[医药卫生—肿瘤]